• Biocon Biologics signed a 10-year partnership supply contract for pertuzumab in Brazil with Bahiafarma and Bionovis.
• Consortium received 100% allocation under Brazil’s Productive Development Partnership program for the HER2-positive breast cancer therapy.
• Deal grants exclusive access to Brazil’s public healthcare market, representing about 70% of national pertuzumab demand.
• Biocon Biologics to receive milestone payments plus a revenue share over the 10-year term.
• Contract includes phased localization of production in Brazil over the mid to long term.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biocon Biologics Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: 7P6IO80IKSATOWGL) on September 08, 2026, and is solely responsible for the information contained therein.